🔗 Visit the ClinicalTrials.gov page for NCT00829660
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. | Diabetes Metab Syndr Obes | 2014 | 1.05 |
| 2 | On the potential of acarbose to reduce cardiovascular disease. | Cardiovasc Diabetol | 2014 | 0.84 |
| 3 | Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point. | Diabetologia | 2013 | 0.77 |
| 4 | Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. | Diabetes Metab Res Rev | 2013 | 0.76 |
| 5 | Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. | Herz | 2016 | 0.75 |
| 6 | Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. | Clin Pharmacol Ther | 2015 | 0.75 |